Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Paclitaxel cationic liposomal - CSPC Pharmaceutical Group

Next Previous
Drug Profile

Paclitaxel cationic liposomal - CSPC Pharmaceutical Group

Alternative Names: HA-131; Paclitaxel cationic liposome for injection - CSPC Pharmaceutical Group

Latest Information Update: 19 Dec 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator CSPC Pharmaceutical Group
  • Class Albumins; Antineoplastics; Diterpenes; Paclitaxels; Skin disorder therapies; Small molecules; Taxanes; Vascular disorder therapies
  • Mechanism of Action Angiogenesis inhibitors; Mitosis inhibitors; Platelet-derived growth factor inhibitors; Proto-oncogene protein c-bcl-2 inhibitors; Tubulin inhibitors; Tubulin polymerisation promoters
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I Colorectal cancer; Liver metastases
  • No development reported Breast cancer; Pancreatic cancer; Solid tumours

Most Recent Events

  • 15 Dec 2025 CSPC ZhongQi Pharmaceutical Technology plans a phase Ib/II trial for Liver cancer (Second-line therapy or greater, Late-stage disease) in December 2025 (Intra-arterial, Infusion) (NCT07282509)
  • 28 Aug 2025 No recent reports of development identified for phase-I development in Solid-tumours(Late-stage disease) in China (Intra-arterial, Infusion)
  • 28 May 2025 No recent reports of development identified for phase-I development in Breast-cancer in China (Parenteral, Injection)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top